Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W T Beck

Showing results (91-100 of 103) with videos related to

Pageof 11
Sort By:
British Journal of Cancer|January 1, 1997
Resistance to the new anti-cancer phospholipid ilmofosine (BM 41 440)J Hofmann, I Utz, M Spitaler, et al.
European Journal of Cancer & Clinical Oncology|December 1, 1989
Failure to detect the P-glycoprotein multidrug resistant phenotype in cases of resistant childhood acute lymphocytic leukaemiaP Ubezio, M Limonta, M D'Incalci, et al.
Oncogene|October 24, 2000
Differences in mutant p53 protein stability and functional activity in teniposide-sensitive and -resistant human leukemic CEM cellsS E Morgan, R Kim, P C Wang, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1997
Decreased levels of topoisomerase II alpha in human renal cell carcinoma lines resistant to etoposideJ M Scheltema, J C Romijn, G J van Steenbrugge, et al.
Oncogene|September 22, 2010
Knockdown of splicing factor SRp20 causes apoptosis in ovarian cancer cells and its expression is associated with malignancy of epithelial ovarian cancerX He, A D Arslan, M D Pool, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 15, 1993
Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNAA V Gudkov, C R Zelnick, A R Kazarov, et al.
Anti-Cancer Drugs|July 11, 1998
Effects of 1,2-naphthoquinones on human tumor cell growth and lack of cross-resistance with other anticancer agentsM E Dolan, B Frydman, C B Thompson, et al.
Leukemia|July 1, 1994
Use of stroma-supported cultures of leukemic cells to assess antileukemic drugs. II. Potent cytotoxicity of 2-chloro-deoxyadenosine in acute lymphoblastic leukemiaM Kumagai, A Manabe, E Coustan-Smith, et al.
Cytotechnology|January 1, 1993
Altered DNA topoisomerase II in multidrug resistanceW T Beck, M K Danks, J S Wolverton, et al.
Cancer Research|October 15, 1987
Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cellsW T Beck, M C Cirtain, M K Danks, et al.
Pageof 11

Showing results (91-100 of 103) with videos related to

Sort By:
Pageof 11
British Journal of Cancer|January 1, 1997
Resistance to the new anti-cancer phospholipid ilmofosine (BM 41 440)J Hofmann, I Utz, M Spitaler, et al.
European Journal of Cancer & Clinical Oncology|December 1, 1989
Failure to detect the P-glycoprotein multidrug resistant phenotype in cases of resistant childhood acute lymphocytic leukaemiaP Ubezio, M Limonta, M D'Incalci, et al.
Oncogene|October 24, 2000
Differences in mutant p53 protein stability and functional activity in teniposide-sensitive and -resistant human leukemic CEM cellsS E Morgan, R Kim, P C Wang, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1997
Decreased levels of topoisomerase II alpha in human renal cell carcinoma lines resistant to etoposideJ M Scheltema, J C Romijn, G J van Steenbrugge, et al.
Oncogene|September 22, 2010
Knockdown of splicing factor SRp20 causes apoptosis in ovarian cancer cells and its expression is associated with malignancy of epithelial ovarian cancerX He, A D Arslan, M D Pool, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 15, 1993
Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNAA V Gudkov, C R Zelnick, A R Kazarov, et al.
Anti-Cancer Drugs|July 11, 1998
Effects of 1,2-naphthoquinones on human tumor cell growth and lack of cross-resistance with other anticancer agentsM E Dolan, B Frydman, C B Thompson, et al.
Leukemia|July 1, 1994
Use of stroma-supported cultures of leukemic cells to assess antileukemic drugs. II. Potent cytotoxicity of 2-chloro-deoxyadenosine in acute lymphoblastic leukemiaM Kumagai, A Manabe, E Coustan-Smith, et al.
Cytotechnology|January 1, 1993
Altered DNA topoisomerase II in multidrug resistanceW T Beck, M K Danks, J S Wolverton, et al.
Cancer Research|October 15, 1987
Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cellsW T Beck, M C Cirtain, M K Danks, et al.
Pageof 11